Treatment with cabergoline for Parkinson’s disease has been linked with increased risk of valvular heart disease. Tan and colleagues found no similar increase in prevalence of valvulopathy in patients receiving cabergoline for hyperprolactinaemia. They support continued use of low-dose cabergoline for patients with hyperprolactinaemia but recommend limiting cumulative dose exposure and advocate more frequent echocardiographic screening in patients with hypertension, cumulative dose exposure of ≤2 mg/week, or those aged over 70 years. Tan et al. (2010) Clinical Endocrinology 73, 369-374.

DOI: 10.1111/j.1365-2265.2010.03827.x